Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings per share estimates for shares of Oncolytics Biotech in a research note issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio expects that the company will earn $1.10 per share for the year. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share.
Separately, Raymond James upgraded shares of Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th.
Read Our Latest Stock Analysis on ONC
Oncolytics Biotech Price Performance
Shares of TSE ONC traded up C$0.09 during trading hours on Tuesday, hitting C$1.14. 297,696 shares of the stock were exchanged, compared to its average volume of 150,025. The company's fifty day simple moving average is C$1.23 and its two-hundred day simple moving average is C$1.36. The company has a market cap of C$87.62 million, a PE ratio of -3.00 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. Oncolytics Biotech has a 1-year low of C$0.98 and a 1-year high of C$2.08.
Oncolytics Biotech (TSE:ONC - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported C($0.12) earnings per share for the quarter, missing analysts' consensus estimates of C($0.11) by C($0.01). During the same quarter in the previous year, the company posted ($0.14) earnings per share.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
